San Francisco, CA, United States of America

Peter J Kushner

USPTO Granted Patents = 17 

 

Average Co-Inventor Count = 4.2

ph-index = 6

Forward Citations = 114(Granted Patents)


Company Filing History:


Years Active: 1992-2025

where 'Filed Patents' based on already Granted Patents

17 patents (USPTO):

Title: The Innovative Contributions of Peter J. Kushner

Introduction

Peter J. Kushner is a notable inventor based in San Francisco, CA, known for his contributions to the field of biotechnology and pharmaceuticals. With a remarkable portfolio of 17 patents, Kushner has made significant strides in cancer treatment and therapeutic advancements.

Latest Patents

Kushner's latest patents reflect his dedication to addressing critical health challenges. One of his notable inventions includes methods of administering estrogen receptor antagonists, aimed at treating cancer. This patent focuses on tetrahydropyrido[3,4-b]indole compounds that serve as complete estrogen receptor antagonists. Additionally, he has developed tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs, which are designed for modulating disorders mediated by estrogen and other related ailments.

Career Highlights

Throughout his career, Peter J. Kushner has collaborated with prominent organizations, including the University of California and Olema Pharmaceuticals, Inc. His work has significantly impacted the pharmaceutical landscape, particularly regarding therapies for hormone-related conditions.

Collaborations

Kushner's journey has been enriched by his collaborations with esteemed colleagues, including Cyrus L. Harmon and David C. Myles. These partnerships have fostered innovation and contributed to the successful development of advanced pharmaceutical solutions.

Conclusion

Peter J. Kushner's inventive spirit and extensive patent portfolio underscore his vital role in advancing medical therapies. His commitment to exploring the potential of estrogen receptor antagonists demonstrates his dedication to improving cancer treatment and enhancing patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…